# EDGAR Filing Document

**Accession Number:** 0001638287
**File Stem:** 0001104659-23-007453
**Filing Date:** 2023-1
**Character Count:** 2791
**Document Hash:** 442f17fa08fe52b2cf2363c168b8e459
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-007453.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001104659-23-007453

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuroBo Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001638287
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 472389984
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 200 BERKELEY ST.
- **STREET 2:** FL 19
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (857) 702-9600

**MAIL ADDRESS:**
- **STREET 1:** 200 BERKELEY ST.
- **STREET 2:** FL 19
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemphire Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150331

January 27, 2023

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, NE

Washington, D.C. 20549

Attention: Jimmy McNamara

---

| | |
|:---|:---|
| **Re:** | **NeuroBo Pharmaceuticals, Inc.** |
|  | **Registration Statement on Form S-3** |
|  | **File No. 333-369365** |
|  | **Acceleration Request** |

---

---

| | |
|:---|:---|
| **Requested Date:** | **January 31, 2023** |
| **Requested Time:** | **5:30 P.M. Eastern Time** |

---

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the **"Company"**) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-369365) (the **"Registration Statement"**) be declared effective at the "Requested Date" and "Requested Time" set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and Garrett Packer of Honigman LLP, counsel to the Company, to make such request on its behalf.

Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone at (313) 465-8137 or Garrett Packer of Honigman LLP by telephone at (313) 465-8090.

*[Signature page follows]*

\*\*\*\*

---

| |
|:---|
| Sincerely, |
| NeuroBo Pharmaceuticals, Inc. |
| /s/ Joseph Hooker |
| Joseph Hooker |
| Interim President and Chief Executive Officer |

---

cc: Phillip Torrence, Honigman LLP <br> Samuel Katz, Honigman LLP <br> Garrett Packer, Honigman LLP